Clinical Management of Head and Neck Cancer Cases: Role of Pharmacogenetics of CYP2 and GSTs
| Autor: | Devendra Parmar, S M Paul Khurana, Munindra Ruwali, Ankur Dhawan, Qamar Rahman, Mohan C. Pant |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Oncology Genetic Markers Cancer Research medicine.medical_specialty Pharmacogenomic Variants medicine.medical_treatment Antineoplastic Agents 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Genetic Predisposition to Disease Precision Medicine Cytochrome P450 Family 2 Glutathione Transferase Evidence-Based Medicine business.industry Squamous Cell Carcinoma of Head and Neck Head and neck cancer Cancer Hematology medicine.disease Precision medicine Head and neck squamous-cell carcinoma Neoplasm Proteins Radiation therapy 030104 developmental biology Treatment Outcome Head and Neck Neoplasms 030220 oncology & carcinogenesis Pharmacogenomics Carcinoma Squamous Cell business Pharmacogenetics |
| Zdroj: | Oncology research and treatment. 39(4) |
| ISSN: | 2296-5262 |
| Popis: | Head and neck squamous cell carcinoma (HNSCC) describes a wide range of malignant tumors which originate in the upper aerodigestive tract and have a multifactorial origin involving both genetic and lifestyle risk factors. The clinical management of head and neck cancer involves surgery, radiotherapy, and chemotherapy. With the advances in treatment strategies for HNSCC, newer targeted therapies are adding to the progress already achieved in the multimodality management of patients although the problems of differences in drug response and adverse drug reactions are still grave concerns. Cancer pharmacogenomics has fast emerged as a new and promising field for the early identification of genetic markers that can predict drug response or toxicity. This could greatly help in identifying genetic markers useful for the selection of optimal drugs, dose, and treatment duration on an individual basis resulting in improved drug efficacy and decreased toxicity. This review focuses on the various treatment modalities available for the clinical management of HNSCC followed by a description of the contribution of genetic variations to chemotherapeutic toxicity and response. Furthermore, studies addressing the association of genetic variants of drug-metabolizing enzymes with treatment response in head and neck cancer are also discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|